Surrender of Share Options
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: GlobeNewswire
Summit Therapeutics plc (‘Summit’ or the ’Company’) Surrender of Share Options Oxford, UK, and Cambridge, MA, US, 8 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that UK-based Executive Director and PDMRs, and employees have voluntarily surrendered options to subscribe for a total of 5,532,461 of the Company’s ordinary shares of one penny nominal value. Following the surrender, the total number of share options which remains outstanding is 3,073,330 (representing 3.7% of the Company’s issued share capital). The surrendered options all have exercise prices in excess of 105p. The changes to Executive Director and PDMR option holdings are summarised in the following table: NamePositionNumber of share options surrenderedNumber of share options still heldGlyn EdwardsChief Executive Officer3,055,096409,959David RoblinChief Operating Officer and President of R&D666,208100,000 The Company’s remuneration po
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $7.00 price target on the stock.MarketBeat
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024Business Wire
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024Business Wire
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsBusiness Wire
SMMT
Earnings
- 5/1/24 - In-Line
SMMT
Sec Filings
- 5/1/24 - Form S-8
- 5/1/24 - Form 8-K
- 5/1/24 - Form 10-Q
- SMMT's page on the SEC website